BRO Drops 5% on Earnings as Shorts Build and Options Pivot

Brown & Brown has just delivered its Q3 results, and the market's verdict is blunt: the stock fell 5% on the day to $67.55, unwinding a chunk of the 16% monthly rally that had built such bullish expectations into the print.

The earnings reaction resets the narrative sharply. The prior three ORTEX notes documented an extraordinary call-heavy options setup, a PCR that had fallen to its 52-week low of 0.1356 on October 23, and a stock trading within reach of consensus price targets. That optimism has now been tested. The one-day move of roughly 7.4% lower on results day is the data point that matters most this week, and it has triggered a rapid repositioning across both the options market and the short-lending desk.

The clearest repositioning signal is in short interest, which has risen fast. SI climbed to 4.86% of the free float on October 27, up nearly 15% on the week and 18% over the past month. That pace of accumulation is notable: short positions were running around 4.2% of float ahead of the print and have jumped by roughly 2.4 million shares in the past two sessions alone. The options market has also shifted. The put/call ratio jumped to 0.2346 on October 27, the highest single-day reading in over a month, up from a cluster of sub-0.15 readings that defined the pre-earnings period. The ratio is still only marginally above its 20-day mean of 0.229, so the z-score of 0.09 does not signal extreme fear, but the direction of travel is a reversal. Borrow conditions remain relaxed: cost to borrow is 0.54%, and availability is ample at roughly 450% of short interest, meaning there is no mechanical squeeze pressure on the new shorts.

The Street's response to the print has been an immediate round of target cuts. Truist Securities, in the most recent action filed this morning, lowered its target from $90 to $85 while keeping a Buy rating. That puts Truist's bull case well above the current price but acknowledges the miss. The broader analyst picture remains split. Morgan Stanley holds an Underweight with a $55 target, the most bearish voice on the Street, while TD Cowen initiated just two weeks ago at Buy with an $82 target. Consensus sits at $74.22, which is still roughly 10% above the post-earnings price, giving the stock a theoretical return potential even after the sell-off. The factor profile underscores the tension: BRO ranks in the 92nd percentile for forward earnings growth and in the 99th percentile on analyst recommendation dispersion, meaning few stocks in the universe have this much disagreement baked in. The PE multiple has compressed to 14.2x and EV/EBITDA to 11.4x following the price drop, both moving lower over the week.

On the company's own data, ORTEX Alt Data recorded BRO's largest Q2 for buyback spend since 2014, with $250 million deployed. Remaining buyback authorisation also rose 261% against the same quarter last year to $900 million. Neither dataset has been measured as a leading indicator for the company's reported figures, so these are context rather than signal, but the scale of capital return heading into a weaker print is worth noting.

Peer action on the day suggests BRO's decline was not purely sector-driven. RYAN fell 4.7% on the same session, but AON was essentially flat and AJG shed only 2.9%. MRSH dropped 2.1% and KNSL fell 2.5%. The sharper move in BRO relative to most peers points to an earnings-specific reaction rather than a macro rotation.

The stock enters the post-earnings period having given back most of October's rally in two sessions. What to watch next is whether short interest continues to build toward the 52-week high of around 5.8% implied by utilization, and whether any of the remaining Buy-rated analysts follow Truist's lead and lower targets further toward the current price.